In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?
Identifieur interne : 000694 ( Pmc/Curation ); précédent : 000693; suivant : 000695In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?
Auteurs : Xavier Pivot ; Laura Mansi ; Loic Chaigneau ; Philippe Montcuquet ; Antoine Thiery-Vuillemin ; Fernando Bazan ; Erion Dobi ; Jean L. Sautiere ; Frederic Rigenbach ; Marie P. Algros ; Steve Butler ; Farid Jamshidian ; Phillip Febbo ; Christer Svedman ; Sophie Paget-Bailly ; Franck Bonnetain ; Christian VillanuevaSource :
- The Oncologist [ 1083-7159 ] ; 2015.
Abstract
The aim of this study was to assess the distribution of Oncotype DX recurrence score (RS) in patients selected for neoadjuvant chemotherapy primarily according to tumor size. Neoadjuvant chemotherapy provides limited benefit with no pathological complete response (pCR) observed in patients with low RS results. Inclusion of patients with such tumors in neoadjuvant trials using pCR as an efficacy measure will dilute the ability to look at treatment effects.
Url:
DOI: 10.1634/theoncologist.2014-0198
PubMed: 25795632
PubMed Central: 4391758
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000694
Links to Exploration step
PMC:4391758Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?</title><author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name></author><author><name sortKey="Mansi, Laura" sort="Mansi, Laura" uniqKey="Mansi L" first="Laura" last="Mansi">Laura Mansi</name></author><author><name sortKey="Chaigneau, Loic" sort="Chaigneau, Loic" uniqKey="Chaigneau L" first="Loic" last="Chaigneau">Loic Chaigneau</name></author><author><name sortKey="Montcuquet, Philippe" sort="Montcuquet, Philippe" uniqKey="Montcuquet P" first="Philippe" last="Montcuquet">Philippe Montcuquet</name></author><author><name sortKey="Thiery Vuillemin, Antoine" sort="Thiery Vuillemin, Antoine" uniqKey="Thiery Vuillemin A" first="Antoine" last="Thiery-Vuillemin">Antoine Thiery-Vuillemin</name></author><author><name sortKey="Bazan, Fernando" sort="Bazan, Fernando" uniqKey="Bazan F" first="Fernando" last="Bazan">Fernando Bazan</name></author><author><name sortKey="Dobi, Erion" sort="Dobi, Erion" uniqKey="Dobi E" first="Erion" last="Dobi">Erion Dobi</name></author><author><name sortKey="Sautiere, Jean L" sort="Sautiere, Jean L" uniqKey="Sautiere J" first="Jean L." last="Sautiere">Jean L. Sautiere</name></author><author><name sortKey="Rigenbach, Frederic" sort="Rigenbach, Frederic" uniqKey="Rigenbach F" first="Frederic" last="Rigenbach">Frederic Rigenbach</name></author><author><name sortKey="Algros, Marie P" sort="Algros, Marie P" uniqKey="Algros M" first="Marie P." last="Algros">Marie P. Algros</name></author><author><name sortKey="Butler, Steve" sort="Butler, Steve" uniqKey="Butler S" first="Steve" last="Butler">Steve Butler</name></author><author><name sortKey="Jamshidian, Farid" sort="Jamshidian, Farid" uniqKey="Jamshidian F" first="Farid" last="Jamshidian">Farid Jamshidian</name></author><author><name sortKey="Febbo, Phillip" sort="Febbo, Phillip" uniqKey="Febbo P" first="Phillip" last="Febbo">Phillip Febbo</name></author><author><name sortKey="Svedman, Christer" sort="Svedman, Christer" uniqKey="Svedman C" first="Christer" last="Svedman">Christer Svedman</name></author><author><name sortKey="Paget Bailly, Sophie" sort="Paget Bailly, Sophie" uniqKey="Paget Bailly S" first="Sophie" last="Paget-Bailly">Sophie Paget-Bailly</name></author><author><name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name></author><author><name sortKey="Villanueva, Christian" sort="Villanueva, Christian" uniqKey="Villanueva C" first="Christian" last="Villanueva">Christian Villanueva</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25795632</idno><idno type="pmc">4391758</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391758</idno><idno type="RBID">PMC:4391758</idno><idno type="doi">10.1634/theoncologist.2014-0198</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000694</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000694</idno><idno type="wicri:Area/Pmc/Curation">000694</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000694</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?</title><author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name></author><author><name sortKey="Mansi, Laura" sort="Mansi, Laura" uniqKey="Mansi L" first="Laura" last="Mansi">Laura Mansi</name></author><author><name sortKey="Chaigneau, Loic" sort="Chaigneau, Loic" uniqKey="Chaigneau L" first="Loic" last="Chaigneau">Loic Chaigneau</name></author><author><name sortKey="Montcuquet, Philippe" sort="Montcuquet, Philippe" uniqKey="Montcuquet P" first="Philippe" last="Montcuquet">Philippe Montcuquet</name></author><author><name sortKey="Thiery Vuillemin, Antoine" sort="Thiery Vuillemin, Antoine" uniqKey="Thiery Vuillemin A" first="Antoine" last="Thiery-Vuillemin">Antoine Thiery-Vuillemin</name></author><author><name sortKey="Bazan, Fernando" sort="Bazan, Fernando" uniqKey="Bazan F" first="Fernando" last="Bazan">Fernando Bazan</name></author><author><name sortKey="Dobi, Erion" sort="Dobi, Erion" uniqKey="Dobi E" first="Erion" last="Dobi">Erion Dobi</name></author><author><name sortKey="Sautiere, Jean L" sort="Sautiere, Jean L" uniqKey="Sautiere J" first="Jean L." last="Sautiere">Jean L. Sautiere</name></author><author><name sortKey="Rigenbach, Frederic" sort="Rigenbach, Frederic" uniqKey="Rigenbach F" first="Frederic" last="Rigenbach">Frederic Rigenbach</name></author><author><name sortKey="Algros, Marie P" sort="Algros, Marie P" uniqKey="Algros M" first="Marie P." last="Algros">Marie P. Algros</name></author><author><name sortKey="Butler, Steve" sort="Butler, Steve" uniqKey="Butler S" first="Steve" last="Butler">Steve Butler</name></author><author><name sortKey="Jamshidian, Farid" sort="Jamshidian, Farid" uniqKey="Jamshidian F" first="Farid" last="Jamshidian">Farid Jamshidian</name></author><author><name sortKey="Febbo, Phillip" sort="Febbo, Phillip" uniqKey="Febbo P" first="Phillip" last="Febbo">Phillip Febbo</name></author><author><name sortKey="Svedman, Christer" sort="Svedman, Christer" uniqKey="Svedman C" first="Christer" last="Svedman">Christer Svedman</name></author><author><name sortKey="Paget Bailly, Sophie" sort="Paget Bailly, Sophie" uniqKey="Paget Bailly S" first="Sophie" last="Paget-Bailly">Sophie Paget-Bailly</name></author><author><name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name></author><author><name sortKey="Villanueva, Christian" sort="Villanueva, Christian" uniqKey="Villanueva C" first="Christian" last="Villanueva">Christian Villanueva</name></author></analytic><series><title level="j">The Oncologist</title><idno type="ISSN">1083-7159</idno><idno type="eISSN">1549-490X</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The aim of this study was to assess the distribution of Oncotype DX recurrence score (RS) in patients selected for neoadjuvant chemotherapy primarily according to tumor size. Neoadjuvant chemotherapy provides limited benefit with no pathological complete response (pCR) observed in patients with low RS results. Inclusion of patients with such tumors in neoadjuvant trials using pCR as an efficacy measure will dilute the ability to look at treatment effects.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name><publisher-loc>Durham, NC, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25795632</article-id><article-id pub-id-type="pmc">4391758</article-id><article-id pub-id-type="publisher-id">T14198</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2014-0198</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>3</subject></subj-group><subj-group subj-group-type="heading"><subject>Breast Cancer</subject></subj-group></article-categories><title-group><article-title>In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?</article-title><alt-title alt-title-type="short">Tumor Size a Criterion for Neoadjuvant Chemotherapy?</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pivot</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref><xref ref-type="aff" rid="aff6"><sup>f</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mansi</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaigneau</surname><given-names>Loic</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Montcuquet</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thiery-Vuillemin</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref><xref ref-type="aff" rid="aff6"><sup>f</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bazan</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dobi</surname><given-names>Erion</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sautiere</surname><given-names>Jean L.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rigenbach</surname><given-names>Frederic</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Algros</surname><given-names>Marie P.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Butler</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jamshidian</surname><given-names>Farid</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Febbo</surname><given-names>Phillip</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Svedman</surname><given-names>Christer</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paget-Bailly</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bonnetain</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villanueva</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><aff>Departments of<target id="aff1" target-type="aff"><sup>a</sup></target>Medical Oncology,<target id="aff2" target-type="aff"><sup>b</sup></target>Gynecology,<target id="aff3" target-type="aff"><sup>c</sup></target>Pathology, and<target id="aff4" target-type="aff"><sup>d</sup></target>Statistics, University Hospital Jean Minjoz, Besançon, France;<target id="aff5" target-type="aff"><sup>e</sup></target>University of Franche-Comté, UMR1098, SFR IBCT, Besançon, France;<target id="aff6" target-type="aff"><sup>f</sup></target>INSERM, UMR1098, Besançon, France;<target id="aff7" target-type="aff"><sup>g</sup></target>EFS Bourgogne Franche-Comté, UMR1098, Besançon, France;<target id="aff8" target-type="aff"><sup>h</sup></target>Genomic Health, Inc., Redwood City, California, USA</aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Xavier Pivot, M.D., Department of Medical Oncology, University Hospital Jean Minjoz, 3 Boulevard Alexandre Fleming, 25030 Besançon Cedex, France. Telephone: <phone>33-3-81-66-93-86</phone>; E-Mail: <email>xavier.pivot@univ-fcomte.fr</email></corresp><fn id="afn1" fn-type="conflict"><p>Disclosures of potential conflicts of interest may be found at the end of this article.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>4</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 12 months and
0 days and was based on the
<volume>20</volume><issue>4</issue><fpage>344</fpage><lpage>350</lpage><history><date date-type="received"><day>17</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>©AlphaMed Press</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="theoncologist_14198.pdf"></self-uri><abstract abstract-type="precis"><p>The aim of this study was to assess the distribution of Oncotype DX recurrence score (RS) in patients selected for neoadjuvant chemotherapy primarily according to tumor size. Neoadjuvant chemotherapy provides limited benefit with no pathological complete response (pCR) observed in patients with low RS results. Inclusion of patients with such tumors in neoadjuvant trials using pCR as an efficacy measure will dilute the ability to look at treatment effects.</p></abstract><abstract><sec><title>Background.</title><p>The Oncotype DX recurrence score (RS) assay has been validated for prediction of 10-year risk of distant recurrence and likelihood of benefit from chemotherapy in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. Patients with high RS tumors have substantial benefit, and patients with low RS tumors have minimal if any benefit from chemotherapy. Tumor size is used as a key parameter when selecting patients for neoadjuvant chemotherapy. The aim of this study was to assess the distribution of RS in patients selected for neoadjuvant chemotherapy primarily according to tumor size.</p></sec><sec><title>Patients and Methods.</title><p>Patients with ER-positive and HER2-negative tumors that were node-negative or had no more than 1 positive node from three trials were included in this study. Oncotype DX was performed at Genomic Health, Inc., blinded to the clinical data. Descriptive statistics were calculated for distribution of RS for all cases.</p></sec><sec><title>Results.</title><p>Of 277 patients, 96 met eligibility criteria, and 81 had sufficient material for analysis. Median tumor size was 40 mm (interquartile range [IQR], 30–50 mm). Grade I, II, and III were observed in 13, 49, and 17 cases, respectively. There was a wide distribution of RS with a median of 21.4 (IQR, 16.05-26.75). In total, 23 (28.3%) had high, 28 (34.6%) intermediate, and 30 (37%) low RS results.</p></sec><sec><title>Conclusion.</title><p>The RS may provide relevant information for neoadjuvant treatment decisions in select patients both in clinical practice and in studies. Inclusion of low RS disease patients in neoadjuvant trials will likely only dilute the ability to look at treatment effects.</p></sec></abstract><kwd-group><kwd>Recurrence score</kwd><kwd>Breast cancer</kwd><kwd>Neoadjuvant chemotherapy</kwd><kwd>Oncotype DX</kwd></kwd-group><counts><page-count count="7"></page-count></counts><custom-meta-group><custom-meta><meta-name> DJS Export </meta-name><meta-value>v1</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4391758
|texte= In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:25795632" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |